BioRem Inc. is set to report its first-quarter financial results on May 27, 2026, following a strong performance last year with record revenues and a substantial order backlog. Investors are eager to see how these factors translate into earnings for the quarter ending March 31.
BioRem Inc. (BRM.V) will release its financial results for the first quarter of 2026 before the market opens on May 27. The company has reported a record order backlog of CA$77 million and a 44% increase in revenue for this quarter. However, the earnings calendar lacks specific EPS figures, leaving investors looking for clarity on profitability.
Advertisement
BioRem Inc.
BRM.V
BRM.V
BioRem Inc.
WealthAwesomeMarket cap
$50.33M
P/E
11.5x
52W high
$3.57
52W low
$1.87
1W change
+0.98%
Beta
0.87
Investor takeaway: With a solid order backlog and revenue growth, BioRem Inc. seems well-positioned for long-term growth, though clarity on earnings will be crucial for investor confidence.
What BioRem's Order Backlog Means for Future Earnings
BioRem's reported order backlog of CA$77 million positions the company for potential revenue growth, but without clear EPS figures, the market will be watching closely to see how this translates into profitability in the upcoming report. The forward P/E ratio of 10.44x suggests that investors are expecting some growth, but clarity on earnings will be key to maintaining confidence.
Bull case
- Strong Backlog: The reported order backlog of CA$77 million shows strong demand for BioRem's services, indicating potential for continued revenue growth.
- Positive Revenue Growth: A 44% increase in revenue for the quarter highlights the company's operational strength and market position.
- Attractive Valuation: With a P/E ratio of 11.48x, BioRem might be a good entry point for value-focused investors, especially given its profit margin of 11.21%.
Bear case
- Lack of EPS Guidance: The absence of EPS figures creates uncertainty about profitability, which could lead to stock price volatility.
- Market Sensitivity: As a smaller company with a market cap of CA$50.33 million, BioRem may be more vulnerable to market fluctuations and investor sentiment.
- Dependence on Backlog: While a large order backlog is promising, it needs to convert into actual revenue and profits to keep investors interested.
BioRem Inc. (BRM.V)
Overview: BioRem Inc. specializes in environmental technology solutions, focusing on air and water treatment systems. The company is based in Canada and serves a variety of industries. What the screen shows: Currently, BioRem's stock is trading at CA$3.54 with a market cap of CA$50.33 million. The company has seen a 1-week increase of about 2%. Risks and watch items: Investors should be aware of potential volatility due to the lack of EPS guidance and the company's reliance on converting its order backlog into actual revenue. Additionally, market sensitivity could impact stock performance.
Advertisement
